Pharmaceutical

Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis

Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis

articleShionogi & Co., Ltd.June 18, 20263/news/positive-topline-results-from-phase-3-oasis-study-evaluating-oral-olorofim-versus-ambisome-followed-by-soc-in-patients-with-invasive-aspergillosis
Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis

About this update from Shionogi & Co., Ltd.

Shionogi & Co., Ltd. (4507) Press ReleaseView Attachment

View stock analysis, news, and events for Shionogi & Co., Ltd.